Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.

Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations

Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations

In this paper we examine the differences between behavioural and attitudinal approaches to segmentation and outline how integration of the two can best be achieved to strengthen segmentation solutions

Segmentation solutions in healthcare are experiencing a welcome comeback. But there appear to be two camps emerging - one camp are proponents of the 'behavioural' segmentation based on secondary sales, script or similar data; the other believe that 'attitudinal' segmentations must be based on primary market research to accurately delineate segment membership, definition and the "whys" that underpin the findings. It's time to take off the gloves and look at the argument from both sides.

read more »

South Korea: The next global player?

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two conflicting global health indicators: longest life expectancy and highest suicide rates.

Over the past two decades South Korea has experienced rapid economic growth. Low unemployment, rising incomes and increased health insurance coverage have all contributed to the development of a robust healthcare sector and catalysed pharmaceutical sales. South Korea is currently the 13th largest pharmaceutical market in the world and the third largest in Asia, with predicted compound annual growth rate (CAGR) of 2.4%. increasing from US$18.6 billion in 2016 to US$20.4 billion by 2020.

read more »

Will gene therapies finally be commercially viable to pharma?

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when attempting to develop this technology. We review gene therapy’s chequered past, look at recent developments in this field and consider the future for gene therapies on their way to market.

Genes are segments of DNA which code instructions for your cells to make proteins. Many inherited disorders are a result of faulty genes which encode incorrect instructions for making specific proteins, either the proteins themselves are defective or the gene may have faulty expression which can result in over-expression so over-production of a certain kind of protein. In the case of cancer, there can be multiple external and internal factors which lead to production of genetically mutated cancerous cells.

read more »

Understanding the chronic disease patient journey in emerging markets

Understanding the chronic disease patient journey in emerging markets

In this paper, we explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these rapidly changing and diverse regions.

With growing urban populations and increasing purchasing power, emerging markets remain an attractive prospect for growth. A high proportion of the urban emerging market population already suffers from chronic diseases and prevalence is set to further increase as lifestyles become closer to those in the West. The chronic disease patient is a critical stakeholder in emerging markets because they often have to pay for their healthcare out of pocket. Moreover, these markets often don’t have formal primary care systems, so the patient is the only constant in the journey. Understanding their journey is critical in order to best leverage these potential new markets.

read more »

US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare

US Presidential Election: The legacy of the Affordable Care Act and the future for healthcare

Our latest Free Thinking white paper explores the legacy of the Affordable Care Act and the future for healthcare

As US citizens prepare to vote for a new President on Tuesday 8th November, we ask, what is the likely impact of a Republican or Democrat win on the future of the ACA, the health system and the pharma industry?
We spoke to John Leifer, author and strategic consultant to the healthcare industry, to see which way he thinks the wind is blowing. 
 

read more »